Admission Date/Time : Patient Restriction 3036 C. HISTORY AND RISK FACTORS. Weight : Heart Failure : Prior PCI 4495 :

Size: px
Start display at page:

Download "Admission Date/Time : Patient Restriction 3036 C. HISTORY AND RISK FACTORS. Weight : Heart Failure : Prior PCI 4495 :"

Transcription

1 A. DEMGRAPHICS Last Name 2000 : First Name 2010 : Middle Name 2020 : SSN 2030 : - - SSN N/A 2031 Patient ID 2040 : (auto) ther ID 2045 : Birth Date 2050 : Race: Sex 2060 : Male Female Patient Zip Code 2065 : Zip Code N/A 2066 White 2070 Black/African American 2071 American Indian/Alaskan Native 2073 Asian 2072 If Yes, Asian Indian 2080 Chinese 2081 Filipino 2082 Japanese 2083 Korean 2084 Vietnamese 2085 ther 2086 Native Hawaiian/Pacific Islander 2074 If Yes, Native Hawaiian 2090 Guamanian or Chamorro 2091 Samoan 2092 ther Island 2093 Hispanic or Latino Ethnicity 2076 : No Yes If Yes, Ethnicity Type: B. EPISDE F CARE Mexican, Mexican-American, Chicano 2100 Puerto Rican 2101 Cuban 2102 ther Hispanic, Latino or Spanish rigin 2103 Arrival Date/Time 3001 : Admission Date/Time : ED Provider s Name, NPI 12202,12201,12203,12204 : Admitting Provider s Name, NPI 3050,3051,3052,3053 : Attending Provider s Name, NPI 3055,3056,3057,3058 :,, Health Insurance 3005 : No Yes If Yes, Payment Source 3010 : HIC # 3015 : Research Study 3020 : No Yes If Yes, Study Name 3025, Patient ID 3030 :, Patient Restriction 3036 C. HISTRY AND RISK FACTRS Private Health Insurance Medicare Medicaid Military Health Care State-Specific Plan (non-medicaid) Indian Health Service Non-US Insurance MBI # : Height : cm Weight : kg Atrial Fibrillation : No Yes Heart Failure : No Yes Atrial Flutter : No Yes Prior PCI 4495 : No Yes Hypertension 4615 : No Yes If Yes, Most Recent PCI Date : Dyslipidemia 4620 : No Yes Prior CABG 4515 : No Yes Currently on Dialysis : No Yes If Yes, Most Recent CABG Date 4520 : Cancer : No Yes Cerebrovascular Disease 4551 : No Yes Prior MI : Diabetes Mellitus : Tobacco Use 4625 : No No Yes Yes If Yes, Stroke : If Yes, TIA : Peripheral Arterial Disease 4610 : Never Former Current - Every Day Current - Some Days Current - Frequency Unknown Unknown if ever smoked If any Current, Tobacco Type 4626 : If Current - Every Day and Cigarettes, Amount 4627 : Cigarettes Cigars Pipe Smokeless Light tobacco use (<10/day) No No No Heavy tobacco use (>=10/day) Yes Yes Yes HME FUNCTINING Walking : Unassisted Assisted Wheelchair/Non-ambulatory Unknown Cognition : Normal Mildly impaired Moderately Impaired Severely Impaired Unknown Basic ADLs : (includes bathing, eating, dressing and toileting) Independent of all ADLs Full assist >=1 ADL Partial assist >=1 ADL Unknown , American College of Cardiology Foundation 26-Jun-2018 ( ) Indicates Basic Data Set (BDS) Page 1 of 10

2 HME MEDICATINS CATEGRY MEDICATIN CDE MEDICATIN PRESCRIBED N YES ACE INHIBITRS (ANGITENSIN CNVERTING ENZYME) ACE (Any) ARB (ANGITENSIN RECEPTRS BLCKERS) ARB (Any) ABA (ALDSTERNE BLCKING ANTAGNIST) ABA (Any) ANTICAGULANT Warfarin ANTIPLATELET Aspirin (Any) BETA-BLCKER Beta Blocker (Any) NEPRILYSIN INHIBITR AND ANGITENSIN II RECEPTR BLCKER Sacubitril and Valsartan NN-STATIN Ezetimibe Fenofibrate INSULIN Insulin (Any) Apixaban NN-VITAMIN K DEPENDENT RAL ANTICAGULANT Dabigatran Edoxaban Rivaroxaban DPP-4 Inhibitor GLP-1 Receptor Agonist Metformin RAL ANTI-GLYCEMICS ther ral Hypoglycemic Pioglitazone SGLT2 Inhibitor Sulfonylurea Clopidogrel P2Y12 INHIBITRS Prasugrel Ticagrelor PCSK9 INHIBITRS Alirocumab Evolocumab STATIN Statin (Any) D. CARDIAC STATUS N PRESENTATIN Patient Type : Low-Risk Chest Pain NSTEMI STEMI Unstable Angina If STEMI, STEMI Setting : Pre-Arrival In-Hospital Means of Transport to First Facility : If Ambulance or Air, Self/Family Ambulance Air EMS First Medical Contact Date and Time : Non-System Reason for Delay , American College of Cardiology Foundation 26-Jun-2018 ( ) Indicates Basic Data Set (BDS) Page 2 of 10

3 D. CARDIAC STATUS N PRESENTATIN Heart Failure : No Yes Cardiogenic Shock : No Yes Heart Rate : bpm Systolic BP : mmhg Cardiac Arrest ut of Hospital 4630 : If Yes, Arrest Witnessed 4631 : If Yes, Arrest after Arrival of EMS 4632 : If Yes, Bystander CPR : No No No No Yes Yes Yes Yes If Yes, First Cardiac Arrest Rhythm 4633 : If Yes, Resuscitation Date/Time : Shockable Not Shockable Unknown 4634 Cardiac Arrest at Transferring Facility 4635 : No Yes Location of First Evaluation : If ED, Transfer ut Date/Time : ED Cath Lab bservation Direct Admit ther If ED, ED Disposition : bservation Inpatient If bservation, bservation rder Date/Time : Acute Coronary Syndrome Symptom Date/Time 12277,12276 : Electrocardiogram Counter : 1 2 ECG Date/Time : STEMI or STEMI Equivalent : If Yes, ECG Findings : If No, ther ECG Findings : Risk Score Documented : No If TIMI Performed, TIMI Score : ST elevation Isolated posterior MI Left bundle branch block ST depression (New or Presumed New) T-Wave inversion (New or Presumed New) Transient ST elevation (Lasting < 20 minutes) ld LBBB None Yes If Yes, Name of Risk Score Performed : TIMI GRACE HEART SYNTAX Score EDACS No Yes No Yes ther ST elevation Isolated posterior MI Left bundle branch block ST depression (New or Presumed New) T-Wave inversion (New or Presumed New) Transient ST elevation (Lasting < 20 minutes) ld LBBB None If GRACE Performed, GRACE Score : Ischemic Symptoms Resolved Before Testing : Chest X-ray Performed : No No Yes Yes Non-Invasive Test Performed : Yes No No Reason No Medical Reason No Pt. Reason If Yes, Non-Invasive Test Performed Type : If Echocardiogram, Nuclear, R Imaging w/cmr, Test Method : Exercise Stress Test (w/o imaging) Echocardiogram Nuclear with SPECT Imaging w/ CMR Cardiac CTA Rest Rest Rest Stress Stress Stress If No No Reason, Planned for After Discharge : No Yes 2017, American College of Cardiology Foundation 26-Jun-2018 ( ) Indicates Basic Data Set (BDS) Page 3 of 10

4 ARRIVAL MEDICATINS CATEGRY MEDICATIN CDE MEDICATIN ADMINISTERED N YES CNTRAINDICATED If Yes, DSE If Yes, START DATE/TIME ANTIPLATELET Aspirin (Any) BETA-BLCKER Beta Blocker (Any) Clopidogrel mg P2Y12 INHIBITRS Prasugrel mg Ticagrelor mg E. ARRIVAL INFRMATIN (CMPLETE IF PATIENT TYPE IS STEMI AND STEMI SETTING IS PRE-ARRIVAL ) Thrombolytic : Yes No No Reason No Medical Reason No Pt. Reason If Yes, Thrombolytic Therapy Date and Time : CMPLETE IF MEANS F TRANSPRT T FIRST FACILITY IS 'AMBULANCE' R 'AIR' EMS Dispatch Date/Time : EMS Leaving Scene Date/Time : EMS Agency Number : EMS Run Number : 12-Lead ECG Performed : If Yes, EMS STEMI Activation Alert : TRANSFERS Transferred from utside Facility : No No No Yes Yes Yes If Yes, Means of Transfer : Ambulance Air Wheelchair Stretcher If Yes, Arrival at utside Facility Date/Time : If Yes, Transfer from utside Facility Date/Time : If Yes, Name and ID of Transferring Facility 12402,12161 : Name, ID Unavailable , American College of Cardiology Foundation 26-Jun-2018 ( ) Indicates Basic Data Set (BDS) Page 4 of 10

5 F. LABS CARDIAC MARKERS Troponin Counter : 1 2 Troponin Collected Date/Time : If any value,troponin Result Date/Time : Troponin Test Location : Lab PC Lab PC If Lab, Troponin Assay, URL : Lab Assay, URL Lab Assay, URL If PC, Troponin Assay, URL : PC Assay, URL PC Assay, URL Troponin Value : ng/ml ng/l µg/l ng/ml ng/l µg/l Initial Creatinine Value : mg/dl Peak Creatinine Value : mg/dl Initial Hemoglobin Value : g/dl Lowest Hemoglobin Value : g/dl Initial Hemoglobin A1c Value : % Not Drawn Not Drawn If any Value, Date/Time : Not Drawn Not Drawn If any Value, Date/Time : Not Drawn Initial INR Value : Not Drawn If any Value, Date/Time : LIPIDS Total Cholesterol : HDL : LDL : Triglycerides : mg/dl Not Drawn mg/dl Not Drawn mg/dl Not Drawn mg/dl Not Drawn G. PRCEDURE INFRMATIN LVEF Assessed : No Yes If Yes, LVEF Measurement : % If No, Planned for after discharge : No Yes Coronary Angiography : Yes No No Reason No Medical Reason No Pt. Reason No System Reason If Yes, Cath Lab Arrival Date/Time : If Yes, Diagnostic Cath perator s Name, NPI 7046,7047,7048,7049 : If Yes, Angiography Date/Time : If Yes, Native Vessel with Stenosis >= 50% 7505 : No NATIVE VESSEL Yes If Yes, Specify Segment(s): SEGMENT 7507 MEASUREMENT (FR EACH SELECTED) Native Stenosis 7508 : Native Stenosis 7508 : % % If Yes, AND Prior CABG 4515 IS Yes, Graft Vessel with Stenosis >= 50% 7525 : No Yes If Yes, Specify Segment(s): GRAFT VESSEL MEASUREMENT (FR EACH SELECTED) SEGMENT 7527 Graft Stenosis 7528 : % Graft Vessel 7529 : LIMA RIMA SVG Radial Graft Stenosis 7528 : % Graft Vessel 7529 : LIMA RIMA SVG Radial CABG : No Yes If Yes, Date/Time : Unknown 7530 Unknown , American College of Cardiology Foundation 26-Jun-2018 ( ) Indicates Basic Data Set (BDS) Page 5 of 10

6 H. PCI PRCEDURE PCI : No Yes If Yes, PCI perator s Name, NPI 7051,7052,7053,7054 : If Yes, Stent Placed : No Yes If Yes, Stent Type : BMS DES Bioabsorbable Unknown If Yes, Arterial Access Site 7320 : Femoral Brachial Radial ther If Yes, PCI Indication : STEMI Primary PCI for Acute STEMI STEMI Rescue (after unsuccessful lytics) STEMI Stable ( <= 12 hrs from Sx) New nset Angina <= 2 months STEMI Stable ( > 12 hrs from Sx) NSTE ACS STEMI Unstable ( >12 hrs from Sx) STEMI (after successful lytics) If No, AND Patient Type is STEMI, Reason Primary PCI Not Performed : No No Reason No Medical Reason Mechanical Ventricular Support 7422 : No Yes If Yes, Device 7423 : CMPLETE IF PCI INDICATIN IS STEMI PRIMARY PCI FR ACUTE STEMI Cath Lab Activated : No Yes If Yes, Cath Lab Activation Date/Time : If Yes, Cath Lab Activation Canceled : No Yes First Device Activation Date/Time 7845 : Patient Centered Reason for Delay in PCI 7850 : No Yes If Yes, Reason 7851 : Difficult Vascular Access Difficulty crossing the culprit lesion Cardiac arrest and/or need for intubation before PCI PCI PRCEDURE MEDICATINS (CMPLETE IF PCI IS 'YES') CATEGRY MEDICATIN CDE 7990 Patient delays in providing consent for PCI Emergent placement of LV support device before PCI ther MEDICATIN ADMINISTERED 7995 N YES Bivalirudin Fondaparinux ANTICAGULANT Heparin Derivative Low Molecular Wt Heparin Unfractionated Heparin Warfarin ANTIPLATELET Vorapaxar GLYCPRTEIN (GP) IIB/IIIA INHIBITRS GP IIb/IIIa Inhibitors (Any) Apixaban NN-VITAMIN K DEPENDENT RAL ANTICAGULANT Dabigatran Edoxaban Rivaroxaban Cangrelor P2Y12 INHIBITRS Clopidogrel Prasugrel Ticagrelor 2017, American College of Cardiology Foundation 26-Jun-2018 ( ) Indicates Basic Data Set (BDS) Page 6 of 10

7 I. EPISDE EVENTS (ALL PATIENT TYPES) (NTE 1: RECRD EACH EVENT SEPARATELY INDICATING THE DATE AND TIME) EVENT(S) EVENT(S) CCURRED IF YES, EVENT DATE/TIME(S) Atrial Fibrillation No Yes Bleeding Access Site No Yes Bleeding Gastrointestinal No Yes Bleeding Genitourinary No Yes Bleeding ther No Yes Bleeding Retroperitoneal No Yes Bleeding Surgical Procedure or Intervention Required No Yes Cardiac Arrest No Yes Cardiogenic Shock No Yes Heart Failure No Yes Intubation No Yes Myocardial Infarction No Yes New Requirement for Dialysis No Yes Stroke Hemorrhagic No Yes Stroke Ischemic No Yes Stroke Undetermined No Yes Transient Ischemic Attack (TIA) No Yes Ventricular Fibrillation No Yes Ventricular Tachycardia No Yes THER EVENTS RBC Transfusion : No Yes If Yes, Transfusion Date : If Yes, CABG Related Transfusion : No Yes NSAID Administered : No Yes CMPLETE IF CARDIAC ARREST UT F HSPITAL 4630 IS YES R CARDIAC ARREST AT TRANSFERRING FACILITY 4635 IS YES R (EVENT(S) IS CARDIAC ARREST AND EVENT(S) CCURRED IS YES ) Hypothermia Induced : Yes No No Reason No Medical Reason If Yes, Hypothermia Induced Date/Time : If Yes, Location of Hypothermia Induction : ED Cath Lab ICU/CCU Level of Consciousness : (A) Alert (V) Verbal (P) Pain (U) Unresponsive Unable to assess 2017, American College of Cardiology Foundation 26-Jun-2018 ( ) Indicates Basic Data Set (BDS) Page 7 of 10

8 J. DISCHARGE Discharge Date/Time : Discharge Provider Name, NPI 10070,10071,10072,10073 : Comfort Measures nly : No Yes If Yes, Date/Time : Enrolled in Clinical Trial During Hospitalization : No Yes If Yes, Type of Clinical Trial(s) : Precluding the use of aspirin in protocol Related to lipid lowering therapy Related to reperfusion therapy Related to AMI Involving new antiplatelet therapies Related to STEMI Involving renin-angiotensin-aldosterone system inhibitor Discharge Status : Alive Deceased If Alive, Cardiac Rehabilitation Referral : No Reason Not Documented No Health Care System Reason Documented No Medical Reason Documented No Patient riented Reason Yes If Alive, Discharge Location : Home Skilled nursing facility Extended care/transitional care unit/rehab ther ther acute care hospital Left against medical advice (AMA) If ther acute care hospital, Transfer Date/Time : If ther acute care hospital, Transfer for Primary PCI : If ther acute care hospital, Transfer for CABG : No No Yes Yes If Alive, Hospice Care : No Yes If Yes, Date/Time : If Deceased, Cause of Death : Acute myocardial infarction Pulmonary Hemorrhage Sudden cardiac death Renal Non-cardiovascular procedure or surgery Heart failure Gastrointestinal Trauma Stroke Hepatobiliary Suicide Cardiovascular procedure Pancreatic Neurological Cardiovascular hemorrhage Infection Malignancy ther cardiovascular reason Inflammatory/Immunologic ther non-cardiovascular reason 2017, American College of Cardiology Foundation 26-Jun-2018 ( ) Indicates Basic Data Set (BDS) Page 8 of 10

9 DISCHARGE MEDICATINS Medications prescribed at discharge are not required for patients who expired, discharged to ther acute care Hospital, AMA, or are receiving Hospice Care. PRESCRIBED AT DISCHARGE If Yes, DSE CATEGRY MEDICATIN CDE YES N N REASN N MEDICAL REASN N PT. REASN LW MDERATE HIGH ABA (ALDSTERNE BLCKING ANTAGNIST) ABA (Any) ACE INHIBITRS (ANGITENSIN CNVERTING ENZYME) ACE (Any) ANTICAGULANT Warfarin ANTIPLATELET Aspirin (Any) ARB (ANGITENSIN RECEPTRS BLCKERS) ARB (Any) BETA-BLCKER Beta Blocker (Any) NEPRILYSIN INHIBITR AND ANGITENSIN II RECEPTR BLCKER Sacubitril/Valsartan NN-STATIN Non-Statin (Any) Apixaban NN-VITAMIN K DEPENDENT RAL ANTICAGULANT Dabigatran Edoxaban Rivaroxaban Clopidogrel P2Y12 INHIBITRS Prasugrel Ticagrelor STATIN Statin (Any) 2017, American College of Cardiology Foundation 26-Jun-2018 ( ) Indicates Basic Data Set (BDS) Page 9 of 10

10 K. FLLW-UP FLLW-UP T CCUR AT 30 DAYS (+14/- 7 DAYS) AND 1 YEAR (+/- 60 DAYS) AFTER THE ADMISSIN DATE Assessment Date : Reference Admission Date/Time : Reference Discharge Date/Time : Method(s) to Determine Status : ffice Visit Medical Records Letter from Medical Provider Phone Call Social Security Death Master File Hospitalized ther Follow-up Status : If Deceased, Date of Death : If Deceased, Cause of Death : Alive Deceased Lost to Follow-up If Alive, Enrolled in Cardiac Rehabilitation Program : If Yes, Attended Cardiac Rehabilitation Program Date : FLLW-UP EVENTS No Acute myocardial infarction Pulmonary Hemorrhage Sudden cardiac death Renal Non-cardiovascular procedure or surgery Heart failure Gastrointestinal Trauma Stroke Hepatobiliary Suicide Cardiovascular procedure Pancreatic Neurological Cardiovascular hemorrhage Infection Malignancy ther cardiovascular reason Inflammatory/Immunologic ther non-cardiovascular reason Yes EVENT(S) EVENT(S) CCURRED IF YES, EVENT DATE CABG: Planned No Yes CABG: Unplanned No Yes Heart failure No Yes Myocardial Infarction: NSTEMI No Yes Myocardial Infarction: STEMI No Yes PCI Planned No Yes PCI Unplanned No Yes Readmission No Yes Renal failure No Yes Stroke: Hemorrhagic No Yes Stroke: Ischemic No Yes Stroke: Undetermined No Yes 2017, American College of Cardiology Foundation 26-Jun-2018 ( ) Indicates Basic Data Set (BDS) Page 10 of 10

GWTG-CAD: Mission: Lifeline Focus July 2017 PMT FORM SELECTION. Pre-Hospital/Arrival

GWTG-CAD: Mission: Lifeline Focus July 2017 PMT FORM SELECTION. Pre-Hospital/Arrival GWTG-CAD: Mission: Lifeline Focus July 2017 PMT FORM SELECTION Page 1 Legend: BOLD = Required ^ = MLL Data Element Admin (Tab) ^Patient ID: Physician/Provider NPI: DOB: / / ^Arrival Date/Time: Race: Hispanic

More information

NCDR CathPCI Registry v4.4 Diagnostic Catheterization and Percutaneous Coronary Intervention Registry

NCDR CathPCI Registry v4.4 Diagnostic Catheterization and Percutaneous Coronary Intervention Registry A. DEMOGRAPHICS Last Name 2000 : First Name 2010 : Middle Name 2020 : SSN 2030 : - - - SSN N/A 2031 Patient ID 2040 : (auto) Other ID 2045 : Birth Date 2050 : *** @ Sex 2060 : *** @ O Male O Female Race:

More information

(auto) à If Yes, Most Recent LVEF Date 4155 : à If Yes, Most Recent LVEF 4160 :

(auto) à If Yes, Most Recent LVEF Date 4155 : à If Yes, Most Recent LVEF 4160 : A. DEMOGRAPHICS Last Name 2000 : First Name 2010 : Middle Name 2020 : SSN 2030 : - - SSN N/A 2031 Patient ID 2040 : (auto) Other ID 2045 : Birth Date 2050 : Sex 2060 : O Male O Female Patient Zip Code

More information

4. Which survey program does your facility use to get your program designated by the state?

4. Which survey program does your facility use to get your program designated by the state? STEMI SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and STEMI

More information

NCDR PVI Registry (Peripheral Vascular Intervention Registry) v 2 Renal Artery Intervention Module- DRAFT ,,, Patient Restriction N683

NCDR PVI Registry (Peripheral Vascular Intervention Registry) v 2 Renal Artery Intervention Module- DRAFT ,,, Patient Restriction N683 Page 1 of 12 A. DEMOGRAPHICS Last Name 2000 : First Name 2010 : Middle Name 2020 : SSN 2030 : - - SSN N/A 2031 Patient ID 2040 : Birth Date 2050 : Sex 2060 : O Male Race: (check all that apply) B. EPISODE

More information

(auto) Zip Code N/A 2066 Race: If Yes, Ethnicity Type:

(auto) Zip Code N/A 2066 Race: If Yes, Ethnicity Type: A. DEMGRAPHICS Last Name 2000 : First Name 2010 : Middle Name 2020 : SSN 2030 : - - SSN N/A 2031 Patient ID 2040 : (auto) ther ID 2045 : Birth Date 2050 : Sex 2060 : Male Female Patient Zip Code 2065 :

More information

New Jersey Cardiac Catheterization Data Registry, Version 2.0 (Please report data only for patients 16 years or older.)

New Jersey Cardiac Catheterization Data Registry, Version 2.0 (Please report data only for patients 16 years or older.) A. ADMINISTRATIVE New Jersey Cardiac Catheterization Data Registry, Version 2.0 (Please report data only for patients 16 years or older.) 1. Facility Code: 2. Facility Name: 3. Procedure Type (Choose only

More information

CHA 2 DS 2 -VASc Thromboembolic Event 4040 : O No O Yes. CHA 2 DS 2 -VASc Vascular Disease 4045 : à If Yes, Vascular Disease Type 4050 :

CHA 2 DS 2 -VASc Thromboembolic Event 4040 : O No O Yes. CHA 2 DS 2 -VASc Vascular Disease 4045 : à If Yes, Vascular Disease Type 4050 : A. DEMGRAPHICS Last Name 2000 : First Name 2010 : Middle Name 2020 : SSN 2030 : - - SSN N/A 2031 Patient ID 2040 : (auto) ther ID 2045 : Birth Date 2050 : Sex 2060 : Male Female Patient Zip Code 2065 :

More information

APPENDIX F: CASE REPORT FORM

APPENDIX F: CASE REPORT FORM APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more

More information

NCDR AFib Ablation Registry v1.0 Atrial Fibrillation (AF) Ablation Interventional Registry

NCDR AFib Ablation Registry v1.0 Atrial Fibrillation (AF) Ablation Interventional Registry A. DEMOGRAPHICS Last Name 2000 : First Name 2010 : Middle Name 2020 : SSN 2030 : - - SSN N/A 2031 Patient ID 2040 : (auto) Other ID 2045 : Birth Date 2050 : Sex 2060 : O Male O Female Patient Zip Code

More information

MBI # : CHA 2 DS 2 -VASc Thromboembolic Event 4040 : O No O Yes. CHA 2 DS 2 -VASc Vascular Disease 4045 : HAS-BLED Bleeding 4095 : O No O Yes

MBI # : CHA 2 DS 2 -VASc Thromboembolic Event 4040 : O No O Yes. CHA 2 DS 2 -VASc Vascular Disease 4045 : HAS-BLED Bleeding 4095 : O No O Yes A. DEMGRAPHICS Last Name 2000 : First Name 2010 : Middle Name 2020 : SSN 2030 : - - SSN N/A 2031 Patient ID 2040 : (auto) ther ID 2045 : Birth Date 2050 : Sex 2060 : Male Female Patient Zip Code 2065 :

More information

GWTG Post-Discharge Follow-up Form

GWTG Post-Discharge Follow-up Form Bold font = Required field Patient ID: Date of Hospital Admission: / / mm / dd / yyyy Date Follow-up Completed: / / mm / dd / yyyy PATIENT LOGISTICS Method used for Patient follow-up: Chart Review Health

More information

STEMI, Non-STEMI, Chest Pain?

STEMI, Non-STEMI, Chest Pain? Minnesota Chest Pain / Acute Coronary Syndrome Tool-Kit Patient with Chest Pain Or Potential Acute Coronary Syndrome STEMI, n-stemi, Chest Pain? Follow MN STEMI Guideline Follow MN n-stemi Guideline Follow

More information

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER: ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM General Instructions: The Heart Failure Hospital Record Abstraction Form is completed for all heart failure-eligible cohort hospitalizations. Refer to

More information

DO NOT SUBMIT OR FAX THIS PAGE TO COR F M L DD MM YY

DO NOT SUBMIT OR FAX THIS PAGE TO COR F M L DD MM YY DO NOT SUBMIT OR FAX THIS PAGE TO COR Patient # Patient Initials of Birth Medical Record Number F M L DD MM YY Patient Name Address Telephone (home) Telephone (work) Expected 6-month Follow-up Family Physician

More information

Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI

Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist physician Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI Outcome objectives of the discussion: At the end of the

More information

2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non ST-Elevation Myocardial Infarction

2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non ST-Elevation Myocardial Infarction 2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non ST-Elevation Myocardial Infarction Ramzi Khalil MD FACC Assistant Professor Allegheny Gen.Hospital AHN Speakers

More information

Acute Coronary Syndrome (ACS) Initial Evaluation and Management

Acute Coronary Syndrome (ACS) Initial Evaluation and Management Acute Coronary Syndrome (ACS) Initial Evaluation and Management Symptoms of Possible ACS Chest discomfort with or without radiation to the arm(s), jaw, or epigastrium Short of breath Weakness Diaphoresis

More information

Acute Coronary syndrome

Acute Coronary syndrome Acute Coronary syndrome 7th Annual Pharmacotherapy Conference ACS Pathophysiology rupture or erosion of a vulnerable, lipidladen, atherosclerotic coronary plaque, resulting in exposure of circulating blood

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital

More information

Quality Payment Program: Cardiology Specialty Measure Set

Quality Payment Program: Cardiology Specialty Measure Set Measure Title * Reportable via PINNACLE α Reportable via Diabetes Collaborative CQMC v1.0 Measure High Priority Measure Cross Cutting Measure Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor

More information

Learning Objectives. Epidemiology of Acute Coronary Syndrome

Learning Objectives. Epidemiology of Acute Coronary Syndrome Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet

More information

Quality Payment Program: Cardiology Specialty Measure Set

Quality Payment Program: Cardiology Specialty Measure Set Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for

More information

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003 Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,

More information

What is a myocardial infarction and how do we treat it? Paul Das Consultant Cardiologist North Wales Cardiac Centre Glan Clwyd Hospital

What is a myocardial infarction and how do we treat it? Paul Das Consultant Cardiologist North Wales Cardiac Centre Glan Clwyd Hospital What is a myocardial infarction and how do we treat it? Paul Das Consultant Cardiologist North Wales Cardiac Centre Glan Clwyd Hospital What is a myocardial infarction? THEY AINT WHAT THEY USED TO BE Case

More information

Consensus Core Set: Cardiovascular Measures Version 1.0

Consensus Core Set: Cardiovascular Measures Version 1.0 Consensus Core Set: Cardiovascular s NQF 0330 Hospital 30-day, all-cause, riskstandardized readmission rate (RSRR) following heart failure hospitalization 0229 Hospital 30-day, all-cause, riskstandardized

More information

Myocardial Infarction In Dr.Yahya Kiwan

Myocardial Infarction In Dr.Yahya Kiwan Myocardial Infarction In 2007 Dr.Yahya Kiwan New Definition Of Acute Myocardial Infarction The term of myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting

More information

Coronary Angiogram Database of South Australia

Coronary Angiogram Database of South Australia Coronary Angiogram Database of South Australia FACILITY 1010 〇 FMC Patient in Follow-up Study? PART A: DEMOGRAPHICS Surname 1020 〇 LMH 〇 No 〇 Yes 〇 RAH 〇 TQEH 2000: First Name 2010: Middle Name Medicare

More information

Acute Coronary Syndrome

Acute Coronary Syndrome ACUTE CORONOARY SYNDROME, ANGINA & ACUTE MYOCARDIAL INFARCTION Administrative Consultant Service 3/17 Acute Coronary Syndrome Acute Coronary Syndrome has evolved as a useful operational term to refer to

More information

Decrease cost of inpatient stay Decrease bed diversions Improve bed utilization (Interqual Criteria) Patient Satisfaction Reduce patient costs

Decrease cost of inpatient stay Decrease bed diversions Improve bed utilization (Interqual Criteria) Patient Satisfaction Reduce patient costs Decrease cost of inpatient stay Decrease bed diversions Improve bed utilization (Interqual Criteria) Patient Satisfaction Reduce patient costs (family hotel, drive back to the VA for next day pick up)

More information

mm / dd / yyyy Heart Failure 4040 à If Yes, New diagnosis 4050 (within 12 months) à If Yes, Etiology 4052 CAD - Stable Angina 4060

mm / dd / yyyy Heart Failure 4040 à If Yes, New diagnosis 4050 (within 12 months) à If Yes, Etiology 4052 CAD - Stable Angina 4060 MRN 1500 : Provider NPI 1550 : A. PATIENT DEMOGRAPHICS Encounter Date 1510 : Encounter TIN 1555 : NCDR PINNACLE Registry v1.6 (CardioEncounters) Data Collection Form Practice Innovation and Clinical Excellence

More information

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and

More information

Acute Coronary Syndromes

Acute Coronary Syndromes Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management

More information

Non ST Elevation-ACS. Michael W. Cammarata, MD

Non ST Elevation-ACS. Michael W. Cammarata, MD Non ST Elevation-ACS Michael W. Cammarata, MD Case Presentation 65 year old man PMH: CAD s/p stent in 2008 HTN HLD Presents with chest pressure, substernally and radiating to the left arm and jaw, similar

More information

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to

More information

Quinn Capers, IV, MD

Quinn Capers, IV, MD Heart Attacks Mended Hearts Presentation, January, 2017 Quinn Capers, IV, MD Associate Professor of Medicine (Cardiovascular Medicine) Director, Transradial Coronary Interventions Division of Cardiovascular

More information

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction Developed in Collaboration with American College of Emergency Physicians and Society for Cardiovascular Angiography and

More information

Controversies in Cardiac Pharmacology

Controversies in Cardiac Pharmacology Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?

More information

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.

More information

NCDR CARE Registry Carotid Artery Revascularization and Endarterectomy Registry Carotid Artery Stenting Form v1.09

NCDR CARE Registry Carotid Artery Revascularization and Endarterectomy Registry Carotid Artery Stenting Form v1.09 NCDR CARE Registry Carotid Artery Revascularization and Endarterectomy Registry Carotid Artery Stenting Fm v1.09 A. PARTICIPANT ADMINISTRATION Participant ID 1000 : Participant Name 1010 : Medicare Provider

More information

Patient Navigator Program: Focus MI Diplomat Hospital Metrics

Patient Navigator Program: Focus MI Diplomat Hospital Metrics Patient Navigator Program: Focus MI Diplomat Hospital Metrics Goal Statement: To reduce avoidable hospital readmissions for patients discharged with acute myocardial infarction (AMI) by supporting a culture

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1

More information

Know the Quality of our Care at Every Step. Kansas City ACS Summit BI-State Cardiovascular Education Consortium

Know the Quality of our Care at Every Step. Kansas City ACS Summit BI-State Cardiovascular Education Consortium Know the Quality of our Care at Every Step Kansas City ACS Summit BI-State Cardiovascular Education Consortium Welcome to the Kansas City ACS Summit Objectives: Follow the flow and care of an ACS patient

More information

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)

More information

Institutional Outcomes Report 2012Q2 Sample Hospital

Institutional Outcomes Report 2012Q2 Sample Hospital Version 2.2 Institutional Outcomes Report 2012Q2 If User desires to publish or otherwise distribute or use, in whole or in part, any aggregate data or reports provided by ACCF, or produced in connection

More information

A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction 1

More information

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor 76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class

More information

Appendix: ACC/AHA and ESC practice guidelines

Appendix: ACC/AHA and ESC practice guidelines Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level

More information

2010 ACLS Guidelines. Primary goals of therapy for patients

2010 ACLS Guidelines. Primary goals of therapy for patients 2010 ACLS Guidelines Part 10: Acute Coronary Syndrome Present : 內科 R1 鍾伯欣 Supervisor: F1 吳亮廷 991110 Primary goals of therapy for patients of ACS Reduce the amount of myocardial necrosis that occurs in

More information

6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS

6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS PREVENTING HOSPITAL READMISSIONS IN CARDIOVASCULAR PATIENTS Christina Cortez Perry, MSN, FNP-C, CCCC Cardiology Coordinator- Corpus Christi Medical Center 1 2 LEARNING OBJECTIVES Identify the target patient

More information

Acute Coronary Syndrome. Sonny Achtchi, DO

Acute Coronary Syndrome. Sonny Achtchi, DO Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification

More information

Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI)

Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI) Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for Artery, Atrial Fibrillation, Hypertension

More information

NCDR PVI Registry (Peripheral Vascular Intervention Registry) v 2 Lower Extremity Module - DRAFT ,,,,,, Patient Restriction N683

NCDR PVI Registry (Peripheral Vascular Intervention Registry) v 2 Lower Extremity Module - DRAFT ,,,,,, Patient Restriction N683 Copyright approvals pending Page 1 of 15 A. DEMOGRAPHICS Last Name 2000 : First Name 2010 : Middle Name 2020 : SSN 2030 : - - SSN N/A 2031 Patient ID 2040 : Birth Date 2050 : Sex 2060 : O Male Race: (check

More information

Quality Measures MIPS CV Specific

Quality Measures MIPS CV Specific Quality Measures MIPS CV Specific MEASURE NAME Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy CAHPS for MIPS Clinician/Group Survey Cardiac Rehabilitation Patient Referral from

More information

STEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology

STEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology STEMI update Vijay Krishnamoorthy M.D. Interventional Cardiology OVERVIEW Current Standard of Care in Management of STEMI Update in management of STEMI Pre-Cath Lab In the ED/Office/EMS. Cath Lab Post

More information

Q1 Contact Information

Q1 Contact Information Q1 Contact Information Answered: 25 Skipped: 0 ANSWER CHOICES Hospital Name of Person Completing Survey Email RESPONSES 100.00% 25 100.00% 25 100.00% 25 # HOSPITAL DATE 1 Research Medical Center 9/26/2018

More information

Management of Acute Myocardial Infarction

Management of Acute Myocardial Infarction Management of Acute Myocardial Infarction Prof. Hossam Kandil Professor of Cardiology Cairo University ST Elevation Acute Myocardial Infarction Aims Of Management Emergency care (Pre-hospital) Early care

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age

More information

Acute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine

Acute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute

More information

New Jersey Department of Health ACUTE STROKE REGISTRY (NJASR) VERSION 2.1

New Jersey Department of Health ACUTE STROKE REGISTRY (NJASR) VERSION 2.1 New Jersey Department of Health ACUTE STROKE REGISTRY (NJASR) VERSION 2.1 A. DEMOGRAPHIC DATA *Hospital Type (1): 1=Primary 2=Comprehensive 3=Other *Hospital Code (2): *Hospital Transferred From Code (3):

More information

DUKECATHR Dataset Dictionary

DUKECATHR Dataset Dictionary DUKECATHR Dataset Dictionary Version of DUKECATH dataset for educational use that has been modified to be unsuitable for clinical research or publication (Created Date and Time: 28OCT16 14:35) Table of

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis

More information

2/26/2013. NCDR.13 Case Scenario Presentation Cath PCI Registry. Disclosures. Objectives. Dashboard Implications of Some Major Metrics

2/26/2013. NCDR.13 Case Scenario Presentation Cath PCI Registry. Disclosures. Objectives. Dashboard Implications of Some Major Metrics NCDR.13 Case Scenario Presentation Cath PCI Registry Dashboard Implications of Some Major Metrics Disclosures Tony Hermann has nothing to disclose Mark Hutcheson has nothing to disclose Cornelia Anderson

More information

FastTest. You ve read the book now test yourself

FastTest. You ve read the book now test yourself FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to

More information

Downloaded from:

Downloaded from: Annemans, L; Danchin, N; Van de Werf, F; Pocock, S; Licour, M; Medina, J; Bueno, H (2016) Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis

More information

convey the clinical quality measure's title, number, owner/developer and contact

convey the clinical quality measure's title, number, owner/developer and contact CMS-0033-P 153 convey the clinical quality measure's title, number, owner/developer and contact information, and a link to existing electronic specifications where applicable. TABLE 20: Proposed Clinical

More information

Coronary Artery Disease Clinical Practice Guidelines

Coronary Artery Disease Clinical Practice Guidelines Coronary Artery Disease Clinical Practice Guidelines Guidelines are systematically developed statements to assist patients and providers in choosing appropriate healthcare for specific clinical conditions.

More information

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A

More information

Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy

Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy Learning Objectives Learn to recognize the high risk patient Discuss effective management of a high risk NSTEMI patient Review CCS

More information

2018 Acute Coronary Syndrome. Robert Bender, DO, FACOI, FACC Central Maine Heart and Vascular Institute

2018 Acute Coronary Syndrome. Robert Bender, DO, FACOI, FACC Central Maine Heart and Vascular Institute 2018 Acute Coronary Syndrome Robert Bender, DO, FACOI, FACC Central Maine Heart and Vascular Institute Definitions: Acute Myocardial Ischemia Unstable Angina Non-ST-Elevation MI (NSTEMI) }2/3 ST-Elevation

More information

Continuing Medical Education Post-Test

Continuing Medical Education Post-Test Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on

More information

2013, American Heart Association

2013, American Heart Association 2013, American Heart Association Mission: Lifeline - Data, Reports and ACTION Registry - GWTG THE MISSION: BETTER HEART ATTACK CARE FOR YOUR COMMUNITY THE LIFELINE: THE AMERICAN HEART ASSOCIATION AND YOU

More information

2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation

2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation 2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation Thierry Gillebert European Society of Cardiology, Slides kindly provided

More information

Sheffield guidelines for the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017)

Sheffield guidelines for the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017) Sheffield guidelines f the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017) Approved by Sheffield Area Prescribing Committee and Sheffield Teaching Hospitals

More information

County of Santa Clara Emergency Medical Services System

County of Santa Clara Emergency Medical Services System County of Santa Clara Emergency Medical Services System Reference # 803 STEMI Data Dictionary STEMI DATA DICTIORY Effective: October 28, 2013 Replaces: January 2009 Review: October 2016 Resources: Policy

More information

GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017

GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017 GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY Nick Collins February 2017 DISCLOSURES Before I commence Acknowledge.. Interventional Cardiologist Perception evolved. Interventional

More information

Effective for Patient Discharges July 01, , American College of Cardiology Foundation 7/1/2017 Page 1 of 130

Effective for Patient Discharges July 01, , American College of Cardiology Foundation 7/1/2017 Page 1 of 130 A. Demographics Seq. #: 2000 Name: Last Name Coding Instructions: Indicate the patient's last name. Hyphenated names should be recorded with a hyphen. Target Value: The value on arrival at this facility

More information

Unstable angina and NSTEMI

Unstable angina and NSTEMI Issue date: March 2010 Unstable angina and NSTEMI The early management of unstable angina and non-st-segment-elevation myocardial infarction This guideline updates and replaces recommendations for the

More information

ST Elevation Myocardial Infarction

ST Elevation Myocardial Infarction ST Elevation Myocardial Infarction Scott M. Lilly, MD, PhD Assistant Professor Clinical Department of Cardiovascular Medicine The Ohio State University Wexner Medical Center Case Presentation 46 year old

More information

Practice-Level Executive Summary Report

Practice-Level Executive Summary Report PINNACLE Registry Metrics 0003, Test Practice_NextGen [Rolling: 1st April 2015 to 31st March 2016 ] Generated on 5/11/2016 11:37:35 AM American College of Cardiology Foundation National Cardiovascular

More information

Adult Diabetes Clinician Guide NOVEMBER 2017

Adult Diabetes Clinician Guide NOVEMBER 2017 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.

More information

NCDR PVI Registry v1.0 Coder's Data Dictionary

NCDR PVI Registry v1.0 Coder's Data Dictionary A. Demographics Seq. #: 2000 Name: Last Name Coding Instructions: Indicate the patient's last name. Hyphenated names should be recorded with a hyphen. Target Value: The value on arrival at this facility

More information

Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings

Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings CMS-1345-P 174 Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings AIM: Better Care for Individuals 1. Patient/Care Giver Experience

More information

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures

More information

European Heart Journal 2015 doi: /eurheartj/ehv320

European Heart Journal 2015 doi: /eurheartj/ehv320 European Heart Journal 2015 doi: 10.1093/eurheartj/ehv320 1 2 Clinical implications of high-sensivity troponin assays European Heart Journal 2015 doi: 10.1093/eurheartj/ehv320 Conditions other than Type

More information

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter

More information

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators

More information

2012 Core Measures. Acute Myocardial Infarction (AMI)

2012 Core Measures. Acute Myocardial Infarction (AMI) 2012 Core Measures Acute Myocardial Infarction (AMI) Aspirin at Arrival Aspirin Prescribed at Discharge Angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) for left ventricular

More information

Timing of Surgery After Percutaneous Coronary Intervention

Timing of Surgery After Percutaneous Coronary Intervention Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet

More information

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial Outcomes in patients with and planned PCI Ph.Gabriel Steg*, Stefan James, Robert A

More information

Lessons learned From The National PCI Registry

Lessons learned From The National PCI Registry Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients

More information

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National

More information

Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017

Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide is based on the 2017 KP National Coronary Artery Disease

More information

NHS QIS National Measurement of Audit Acute Coronary Syndrome

NHS QIS National Measurement of Audit Acute Coronary Syndrome NHS QIS National Measurement of Audit Acute Coronary Syndrome Things have changed based on the experience and feedback from the first cycle of measurement and, for the better we think! The Acute Coronary

More information

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Measure #204 (NQF 0068): Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY

More information

ST Elevation Myocardial Infarction

ST Elevation Myocardial Infarction ST Elevation Myocardial Infarction Scott M. Lilly, MD, PhD Assistant Professor Clinical Department of Cardiovascular Medicine The Ohio State University Wexner Medical Center Outline Case Presentation STEMI

More information

North Wales Cardiac Network Guidelines on oral antiplatelet therapy in cardiovascular disease

North Wales Cardiac Network Guidelines on oral antiplatelet therapy in cardiovascular disease Guidelines on oral antiplatelet therapy in cardiovascular disease This guidance should be considered as one part of the wider therapeutic management of patients. The indication for antiplatelet therapy

More information

Acute Myocardial Infarction. Willis E. Godin D.O., FACC

Acute Myocardial Infarction. Willis E. Godin D.O., FACC Acute Myocardial Infarction Willis E. Godin D.O., FACC Acute Myocardial Infarction Definition: Decreased delivery of oxygen and nutrients to the myocardium Myocardial tissue necrosis causing irreparable

More information